官方服务：
资源简介：
All available raw human data other than Table 1-3 are presented. Datasets legend is also available.
应用场景：
创建时间：
2025-06-09
相关数据集
Dataset from Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
This trial is conducted globally. The aim of this trial is to investigate dose-finding of semaglutide administered subcutaneously once daily versus placebo and liraglutide in subjects with type 2 diab
NIAID Data Ecosystem50
Discovery of Selenium-Containing Derivatives as Potent and Orally Bioavailable GLP-1R Agonists
Glucagon-like peptide-1 receptor (GLP-1R) is a well-established target for the treatment of type 2 diabetes mellitus (T2DM) and obesity. The development of orally bioavailable and long-acting small-mo
Figshare2025-01-17 更新50
Qi et. al. "A brush-polymer/exendin-4 conjugate reduces blood glucose levels for up to five days and eliminates poly(ethylene glycol) antigenicity" raw data
This file contains raw data that support the findings reported in Qi et. al. article titled "A brush-polymer/exendin-4 conjugate reduces blood glucose levels for up to five days and eliminates poly(et
Figshare2016-11-29 更新20
Allosteric Modulators Enhancing GLP‑1 Binding to GLP-1R via a Transmembrane Site
The glucagon-like peptide-1 receptor (GLP-1R) is a well-established drug target for the treatment of type II diabetes. The development of small-molecule positive allosteric modulators (PAMs) of GLP-1R
NIAID Data Ecosystem50
DataSheet1_Efficacy and Safety of Subcutaneous and Oral Semaglutide Administration in Patients With Type 2 Diabetes: A Meta-Analysis.zip
Background: This meta-analysis aimed to combine the data available from clinical trials to assess the effects of subcutaneous and oral semaglutide administration on glycemic control, weight management
NIAID Data Ecosystem30
